Rondol cooperates with BASF and QUB against child malaria

In recognition of World Malaria Day this week, we proudly announce a newly initiated research collaboration between BASF Pharma Solutions, Queen’s University Belfast, and Rondol Group with the goal of developing a model, robust, child-friendly dosage form based on anti-malarial active pharmaceutical ingredients (APIs) while using BASF excipients, hot-melt extrusion (HME) technology, and a Rondol continuous manufacturing platform installed at Queens University in Belfast.

Our organizations are jointly passionate about giving each child in the world the possibility to grow in an environment that promotes health, safety, and protection from infectious diseases.

We see this research collaboration as a unique opportunity to combine our personal passions and technical expertise to drive for efficient, child-friendly dosage forms at an acceptable cost and manufacturing footprint for communities in malaria-stricken areas of our planet.

Follow us on Linkedin for updates and future webinars from our project team!